Cirujano General

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board

>Journals >Cirujano General >Year 2010, Issue 3

Medina FH
Multidisciplinary management of hepatic metastases from colorectal cancer
Cir Gen 2010; 32 (3)

Language: Espańol
References: 44
Page: 180-186
PDF: 4. Kb.

Full text


Objective: To review the main controversies in the multidisciplinary management of hepatic metastatic disease from colorectal cancer.
Setting: Third level health care center. Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”.
Design: Review of the literature.
Material and methods: A review of the literature was made with respect to the new treatments that have given rise to controversies in terms of the adequateness of combining pharmacological agents, the optimal sequence of their use in relation to the performed surgery, and the impact of these treatments on the surgical outcome. The assessed therapies were neoadjuvant chemotherapy, ablation versus resection of the metastatic lesion, and hepatic resection in the presence of extrahepatic disease.
Results: Neoadjuvant chemotherapy can: 1) serve as an in vivo chemosensitivity test that will guide in choosing the therapeutic scheme after surgery; 2) eliminate micrometastatic disease already present but not visible in the hepatic parenchyma, 3) help in reducing the tumoral volume, which will allow performing a more conservative resection and increase the rate of complete surgical resection of the metastasis. The response to chemotherapy can become an important prognostic marker. Its administration has been associated with pathological changes in the hepatic parenchyma; however, this does not impact morbidity, mortality, or survival. Regarding ablation versus resection of lesions, the results are not comparable because of the lack of prospective studies. This leaves resection as the golden standard. Regarding hepatic resection in the presence of extrahepatic disease, it is known that resection of hepatic metastases in the presence of ganglionic metastases in the portal hilum should only be done in carefully chosen patients, as it implies a poor prognostic factor. Resection of synchronous pulmonary and hepatic metastases in well chosen patients is associated with a long term survival potential. Finally, the change in the concept that peritoneal metastases not always represent systemic dissemination of the disease, and could be a form of regional recurrence accessible to localized treatment is discussed.
Conclusion: The changes in the concepts regarding hepatic resection in colorectal cancer must be assessed in controlled clinical trials to reach a clear definition.

Key words: Colorectal cancer, metastases, liver.


  1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.

  2. Villalobos JJ, Vargas F, Villarreal HA, et al. A 10-year prolective study on cancer of the digestive system. Rev Gastroenterol Mex 1990; 55: 17-24.

  3. Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005; 23: 2038-2048.

  4. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-321.

  5. Khatri VP, Petrelli NJ, Belghiti J. Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol 2005; 23: 8490-8499.

  6. Kemeny MM, Adak S, Gray B Macdonald JS, Smith T, Lipsitz S, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastasis in combination with continuous infusion of chemotherapy-an intergroup study. J Clin Oncol 2002; 20: 1499-1505.

  7. Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006; 24: 4976-4982.

  8. Langer B, Bleiberg H, Labianca R. Fluoruracil (FU) plus L-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GVIO) randomized trial. J Clin Oncol 2002; 20:149a (abstr 592).

  9. Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008; 26: 4906-4911.

  10. Ychou M, Hohenberger W, Thezenas S, Navarro M, Maurel J, Bokemeyer C, et al. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 2009; 20: 1964-1970.

  11. Allen PJ, Kemeny N, Jarnagin W, DeMatteo R, Blumgart L, Fong Y. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 2003; 7: 109-115.

  12. Adam R, Wicherts DA, de Hass RJ, Aloia T, Lévi F, Paule B, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol 2008; 26: 1635-1641.

  13. Peppercorn PD, Reznek RH, Wilson P, Slevin ML, Gupta RK. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer 1998; 77: 2008-2011.

  14. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15: 460-466.

  15. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005; 200: 845-853.

  16. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24: 2065-2072.

  17. Kooby DA, Fong Y, Suriawinata A, Gonen M, Allen PJ, Klimstra DS, et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 2003; 7: 1034-1044.

  18. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup Trial 40983): a randomized controlled trial. Lancet 2008; 371: 1007-1016.

  19. Aloia T, Sebagh M, Plasse M, Karam V, Lévi F, Giacchetti S, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006; 24: 4983-4990.

  20. Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008; 26: 1830-1835.

  21. Benoist S, Brouquet A, Penna C, Julié C, El Hajjam M, Chagnon S, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006; 24: 3939-3945.

  22. Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004; 240: 1052-1061.

  23. McGahan JP, Brock JM, Tesluk H, Gu WZ, Schneider P, Browning PD. Hepatic ablation with use of radio-frequency electrocautery in the animal model. J Vasc Interv Radiol 1992; 3: 291-297.

  24. Abitabile P, Hartl U, Lange J, Maurer CA. Radiofrequency ablation permits an effective treatment for colorectal liver metastasis. Eur J Surg Oncol 2007; 33: 67-71.

  25. Berber E, Tsinberg M, Tellioglu G, Simpferdofer CH, Siperstein AE. Resection versus laparoscopic radiofrequency thermal ablation of solitary colorectal liver metastasis. J Gastrointest Surg 2008; 12: 1967-1972.

  26. Abdalla EK, Vauthey JN. Colorectal metastases: resect or ablate? Ann Surg Oncol 2006; 13: 602-603.

  27. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239: 818-825.

  28. Machi J, Oishi AJ, Sumida K, Sakamoto K, Furumoto NL, Oishi RH, et al. Long-term outcome of radiofrequency ablation for unresectable liver metastases from colorectal cancer: evaluation of prognostic factors and effectiveness in first- and second-line management. Cancer J 2006; 12: 318-326.

  29. van Duijnhoven FH, Jansen MC, Junggeburt JM, van Hillegersberg R, Rijken AM, van Coevorden F, et al. Factors influencing the local failure rate of radiofrequency ablation of colorectal liver metastases. Ann Surg Oncol 2006; 13: 651-658.

  30. Heslin MJ, Medina-Franco H, Parker M, Vickers SM, Aldrete J, Urist MM. Colorectal hepatic metastases: resection, local ablation, and hepatic artery infusion pump are associated with prolonged survival. Arch Surg 2001; 136: 318-323.

  31. Wood TF, Rose DM, Chung M, Allegra DP, Foshang LJ, Bilchik AJ. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol 2000; 7: 593-600.

  32. Curley SA, Izzo F, Abdalla E, Vauthey JN. Surgical treatment of colorectal cancer metastasis. Cancer Metastasis Rev 2004; 23: 165-182.

  33. Lu MD, Chen JW, Xie XY, Liu L, Huang XQ, Liang LJ, et al. Hepatocellular carcinoma: US-guided percutaneous microwave coagulation therapy. Radiology 2001; 221: 167-172.

  34. Ahmad A, Chen SL, Kavanagh MA, Allegra DP, Bilchik AJ. Radiofrequency ablation of hepatic metastases from colorectal cancer: are newer generation probes better? Am Surg 2006; 72: 875-879.

  35. August DA, Sugarbaker PH, Schneider PD. Lymphatic dissemination of hepatic metastases. Implications for the follow-up and treatment of patients with colorectal cancer. Cancer 1985; 55: 1490-1494.

  36. Beckurts KT, Holscher AH, Thorban S, Bollschweiler E, Siewert JR. Significance of lymph node involvement at the hepatic hilum in the resection of colorectal liver metastases. Br J Surg 1997; 84: 1081-1084.

  37. Rosen CB, Nagorney DM, Taswell HF, Helgeson SL, Ilstrup DM, van Heerden JA, et al. Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma. Ann Surg 1992; 216: 493-505.

  38. Laurent C, Sa Cunha A, Rullier E, Smith D, Rullier A, Saric J. Impact of microscopic hepatic lymph node involvement on survival after resection of colorectal liver metastasis. J Am Coll Surg 2004; 198: 884-891.

  39. Grobmyer SR, Wang L, Gonen M, Fong Y, Klimstra D, D’Angelica M, et al. Perihepatic lymph node assessment in patients undergoing partial hepatectomy for malignancy. Ann Surg 2006; 244: 260-264.

  40. Adam R, de Haas RJ, Wicherts DA, Aloia TA, Delvart V, Azoulay D, et al. Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement? J Clin Oncol 2008; 26: 3672-3680.

  41. Carpizo DR, Are C, Jarnagin W, Dematteo R, Fong Y, Gönen M, et al. Liver resection for metastatic colorectal cancer in patients with concurrent extrahepatic disease: results in 127 patients treated at a single center. Ann Surg Oncol 2009; 16: 2138-2146.

  42. Lee WS, Yun SH, Chun HK, Lee WY, Yun HR, Kim J, et al. Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Colorectal Dis 2007; 22: 699-704.

  43. Vogelsang H, Haas S, Hierholzer C, Berger U, Siewert JR, Präuer H. Factors influencing survival after resection of pulmonary metastases from colorectal cancer. Br J Surg 2004; 91: 1066-1071.

  44. Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg 2006; 243: 212-222.

>Journals >Cirujano General >Year 2010, Issue 3

· Journal Index 
· Links 

Copyright 2019